Where would you like to sign in?

Stem Cell Therapy Announces That Merger Is Progressing on Schedule

TAMPA, FL--(Marketwire - December 23, 2009) - Stem Cell Therapy International, Inc. (OTCBB: SCII) announced that its pre-closing conditions for its merger with
Histostem Co. Ltd. ("Histostem") are proceeding on schedule with an
expected close of the merger in January 2010.

Shareholders have approved changing the Company's name to AmStem
Corporation and approved an increase in authorized shares. The Company has
filed an application with FINRA for the official name change to AmStem
Corporation. AmStem Corporation (SCII) will be the parent company of
Histostem and AmStem International, Inc. (Nevada Corporation), the wholly
owned subsidiary, established for international distribution of cosmetic
products and treatments.

Furthermore, the Company has issued the 93,863,357 shares, currently held
in escrow, required to consummate the acquisition of a 90% controlling
interest in the securities of Histostem. Following the closing, the
Company expects to have approximately 175,753,995 shares outstanding. This
fully diluted share figure includes the estimate of 13,181,535 shares which
will be issued within 5 days of the closing to settle previous litigation
as per the merger agreement. The shares held by Histostem are not expected
to be registered or distributed.

David Stark, President and CEO of SCII, commented, "We have been making
considerable progress fulfilling the obligations within our agreement with
Histostem and anticipate the merger will be completed very soon. This
merger creates one of the first fully merged Pacific Rim and U.S. stem cell
companies and we look forward to beginning this new chapter in our
corporate development. As with all international mergers, progress often
takes longer than expected, however all parties are excited about creating
a leading, international stem cell research, treatment and product
distribution company."

About Stem Cell Therapy International, Inc.

Stem Cell Therapy International, Inc. (OTCBB: SCII) is in the field of
regenerative medicine. SCII (soon to have its name changed to AmStem
Corporation) is a company devoted to the treatment of patients with stem
cell transplantation therapy as well as providing the supplies of
biological solutions containing new lines of stem cell products.

About AmStem International Corporation

AmStem is a new biotechnology company based in Northern California, in the
watershed of stem cell innovation fueled by President Obama's recent
announcement to lift Federal funding limitations for stem cell research.
AmStem provides biotherapeutic and cosmetic stem cell products, stem cell
collection and storage know-how, and access to nanotechnology vital to
cutting edge stem cell research. Its web site is under construction at
www.amsteminc.com.

About Histostem Co. Ltd.

Histostem was founded in Seoul, Korea in 2000. To date it has treated more
than 500 patients with stem cells and currently has approximately
50 full-time employees and several part-time employees. Histostem's
intellectual property portfolio consists of 6 patents that have been
granted and 5 patents pending. To its knowledge, Histostem is one of the
very few stem cell companies in the world currently earning several million
dollars in income from its products and technology. A comprehensive list of
Histostem's achievements can be found at the company's website
http://www.histostem.co.kr (click on English version when entering the
site).

Forward-Looking Statements

Some of the statements included in this press release, particularly those
anticipating future clinical and business prospects for Stem Cell Therapy
International, Inc., may be forward-looking statements that involve a
number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in
the Private Securities Litigation Reform Act of 1995. Among the factors
that could cause our actual results to differ materially are the following:
our ability to obtain necessary capital, our ability to successfully
complete the merger, successfully complete clinical trials; our ability to
meet anticipated development timelines, our ability to establish global
market for the cord blood cells, clinical trial results, successfully
consummate future acquisitions, manufacturing capabilities or other
factors; and other risk factors identified from time to time in our reports
filed with the Securities and Exchange Commission. Any forward-looking
statements set forth in this press release speak only as of the date of
this press release. We do not intend to update any of these forward-looking
statements to reflect events or circumstances that occur after the date
hereof.